Clinical trial
An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial
NCT02031432 is registered in ClinicalTrials.gov with Tris Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial
- Lead sponsor
- Tris Pharma, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 18, 2013
- Completion date
- May 3, 2016
- Enrollment
- 76 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.